Skip to content

Advertisement

Articles

Sort by
Page 1 of 39
  1. Content type: Review

    Multiple myeloma is the second most frequent hematological malignancy in the western world and remains incurable, predominantly due to acquired drug resistance and disease relapse. The highly conserved Wnt sig...

    Authors: Ingrid Spaan, Reinier A. Raymakers, Anja van de Stolpe and Victor Peperzak

    Citation: Journal of Hematology & Oncology 2018 11:67

    Published on:

  2. Content type: Case report

    Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as ...

    Authors: Carmela De Santo, Paul Cheng, Andrew Beggs, Sharon Egan, Alberto Bessudo and Francis Mussai

    Citation: Journal of Hematology & Oncology 2018 11:68

    Published on:

  3. Content type: Letter to the Editor

    Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its treatment. The protective effects of the niche in which it develops has been well documented; however, little has be...

    Authors: Rachel E. Piddock, Christopher R. Marlein, Amina Abdul-Aziz, Manar S. Shafat, Martin J. Auger, Kristian M. Bowles and Stuart A. Rushworth

    Citation: Journal of Hematology & Oncology 2018 11:66

    Published on:

  4. Content type: Review

    Disruption of the physiologic balance between cell proliferation and cell death is an important step of cancer development. Increased resistance to apoptosis is a key oncogenic mechanism in several hematologic...

    Authors: Guilherme Fleury Perini, Glaciano Nogueira Ribeiro, Jorge Vaz Pinto Neto, Laura Tojeiro Campos and Nelson Hamerschlak

    Citation: Journal of Hematology & Oncology 2018 11:65

    Published on:

  5. Content type: Review

    The deeper understanding of non-coding RNAs has recently changed the dogma of molecular biology assuming protein-coding genes as unique functional biological effectors, while non-coding genes as junk material ...

    Authors: Nicola Amodio, Lavinia Raimondi, Giada Juli, Maria Angelica Stamato, Daniele Caracciolo, Pierosandro Tagliaferri and Pierfrancesco Tassone

    Citation: Journal of Hematology & Oncology 2018 11:63

    Published on:

  6. Content type: Research

    Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azaciti...

    Authors: C. Roolf, A. Richter, C. Konkolefski, G. Knuebel, A. Sekora, S. Krohn, J. Stenzel, B. J. Krause, B. Vollmar, H. Murua Escobar and C. Junghanss

    Citation: Journal of Hematology & Oncology 2018 11:62

    Published on:

  7. Content type: Research

    Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. ...

    Authors: Ying Wang, Yingxi Xu, Saisai Li, Jia Liu, Yanyan Xing, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Min Wang and Jianxiang Wang

    Citation: Journal of Hematology & Oncology 2018 11:60

    Published on:

  8. Content type: Case report

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months. Pediatric patien...

    Authors: Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal and Anthony Stein

    Citation: Journal of Hematology & Oncology 2018 11:61

    Published on:

  9. Content type: Research

    Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting ...

    Authors: Qian Huang, Jiajia Xia, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, Munish Kumar, Zhiyuan Zhou, Ling Li, Zhaoyang Zeng, Ken H. Young, Qing Yi, Mingzhi Zhang and Yong Li

    Citation: Journal of Hematology & Oncology 2018 11:58

    Published on:

  10. Content type: Review

    CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolum...

    Authors: Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang and Stephen M. Ansell

    Citation: Journal of Hematology & Oncology 2018 11:57

    Published on:

  11. Content type: Correction

    The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.

    Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin…

    Citation: Journal of Hematology & Oncology 2018 11:56

    Published on:

    The original article was published in Journal of Hematology & Oncology 2018 11:12

  12. Content type: Research

    Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Eit...

    Authors: Nicole Santoro, Myriam Labopin, Federica Giannotti, Gerard Ehninger, Dietger Niederwieser, Arne Brecht, Matthias Stelljes, Nicolaus Kröger, Herman Einsele, Matthias Eder, Michael Hallek, Bertram Glass, Jürgen Finke, Fabio Ciceri, Mohamad Mohty, Annalisa Ruggeri…

    Citation: Journal of Hematology & Oncology 2018 11:55

    Published on:

  13. Content type: Research

    C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h...

    Authors: Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G. Pestell, Xinwei Han and Kongming Wu

    Citation: Journal of Hematology & Oncology 2018 11:53

    Published on:

  14. Content type: Research

    Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not yet been comprehensively characterized in acute mye...

    Authors: Arvind Singh Mer, Johan Lindberg, Christer Nilsson, Daniel Klevebring, Mei Wang, Henrik Grönberg, Soren Lehmann and Mattias Rantalainen

    Citation: Journal of Hematology & Oncology 2018 11:52

    Published on:

  15. Content type: Correction

    The original article [1] contains an inadvertent error in the following sentence in the Abstract regarding the erroneous description of Ser/Thr kinases as ‘phylogenetically related’:

    Authors: Sabrina Manni, Marilena Carrino and Francesco Piazza

    Citation: Journal of Hematology & Oncology 2018 11:51

    Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:157

  16. Content type: Research

    In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed mult...

    Authors: Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel and Philippe Moreau

    Citation: Journal of Hematology & Oncology 2018 11:49

    Published on:

  17. Content type: Research

    Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3-N-...

    Authors: Tianxiao Yang, Yilin Wang, Wenjuan Dai, Xixi Zheng, Jing Wang, Shushu Song, Lan Fang, Jiangfan Zhou, Weicheng Wu and Jianxin Gu

    Citation: Journal of Hematology & Oncology 2018 11:50

    Published on:

  18. Content type: Review

    Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models...

    Authors: Rosemarie Tremblay-LeMay, Nasrin Rastgoo and Hong Chang

    Citation: Journal of Hematology & Oncology 2018 11:46

    Published on:

  19. Content type: Review

    First identified in 1974, m6A RNA methylation, which serves as a predominant internal modification of RNA in higher eukaryotes, has gained prodigious interest in recent years. Modifications of m6A are dynamic and...

    Authors: Yutian Pan, Pei Ma, Yu Liu, Wei Li and Yongqian Shu

    Citation: Journal of Hematology & Oncology 2018 11:48

    Published on:

  20. Content type: Review

    Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic...

    Authors: Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu and Kongming Wu

    Citation: Journal of Hematology & Oncology 2018 11:47

    Published on:

  21. Content type: Research

    Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such ...

    Authors: Erhao Zhang, Jieyi Gu, Jianpeng Xue, Chenyu Lin, Chen Liu, Mengwei Li, Jingchao Hao, Sarra Setrerrahmane, Xiaowei Chi, Weiyan Qi, Jialiang Hu and Hanmei Xu

    Citation: Journal of Hematology & Oncology 2018 11:44

    Published on:

  22. Content type: Research

    Mantle cell lymphoma (MCL) is an incurable B cell-derived malignant tumor with a median overall survival of 4–5 years. Mer tyrosine kinase (MerTK) has been reported to be aberrantly expressed in leukemia, mela...

    Authors: Cunzhen Shi, Xiangqun Li, Xiaogan Wang, Ning Ding, Lingyan Ping, Yunfei Shi, Lan Mi, Yumei Lai, Yuqin Song and Jun Zhu

    Citation: Journal of Hematology & Oncology 2018 11:43

    Published on:

Page 1 of 39
JHO logo

2016 Journal Metrics

Advertisement